All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

CJC-1295 with DAC peptide

CJC-1295 with DAC is a synthetic peptide studied for its ability to stimulate the natural release of growth hormone (GH). It belongs to a class of compounds known as growth hormone–releasing hormone (GHRH) analogues, which influence hormonal pathways regulating growth hormone secretion.

CJC-1295 with DAC contains a Drug Affinity Complex (DAC) modification designed to extend the peptide’s half-life and prolong its biological activity.

Because of this modification, CJC-1295 with DAC peptide has been investigated in research related to endocrine regulation, metabolism, and growth hormone physiology.

How CJC-1295 with DAC peptide works

CJC-1295 with DAC stimulates GHRH receptors in the pituitary gland, which triggers the release of growth hormone through the body’s endocrine system.

Research suggests that the peptide may:

  • stimulate growth hormone secretion from the pituitary gland

  • increase circulating insulin-like growth factor-1 (IGF-1) through activation of the GH axis

  • influence metabolic pathways related to energy balance and tissue growth

The DAC modification allows the peptide to bind to plasma proteins, which can:

  • extend its circulating half-life

  • produce sustained stimulation of GH release

  • maintain elevated levels of IGF-1 for longer periods in experimental models

Clinical trials and evidence

Research involving CJC-1295 has included laboratory studies and early clinical trials examining growth hormone stimulation and endocrine signaling. Studies have explored:

  • stimulation of GH and IGF-1 levels in humans

  • potential applications in growth hormone deficiency research

  • regulation of endocrine and metabolic pathways

Although some early studies demonstrated increases in circulating growth hormone and IGF-1 levels, CJC-1295 with DAC has not progressed to widespread pharmaceutical approval, and most available information comes from experimental research.

Possible side effects of CJC-1295 with DAC peptide:

Because CJC-1295 with DAC affects the growth hormone axis, potential side effects may include:

  • headache

  • flushing

  • mild water retention

  • fatigue

  • injection site reactions

As with many investigational peptides affecting endocrine pathways, the long-term safety profile has not been fully established.

CJC-1295 with DAC is considered an experimental peptide studied primarily in endocrine and metabolic research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

CJC-1295 with DAC
Action: Long acting GH stimulation | Category: GHRH analog
Experimental dosage: 300–500 mcg | Frequency: every week | Timing: freely | Cycle on: 8 weeks; long half‑life and cumulative effect — do not administer more often than every 7 days; assess tolerability at weeks 4 and 8. — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 8 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:AOD9604, CJC-1295 NO DAC, GHRP-2, GHRP-6, Hexarelin, Ipamorelin

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged